Cooper's CF Crew

To see this medicine now available for so many different cystic fibrosis genetic mutations is amazing!!

FDA Approves Trikafta for 94 Additional Rare CFTR Mutations The U.S. Food and Drug Administration (FDA) today approved the expansion of Trikafta (elexacaftor/tezacaftor/ivacaftor) to people with cystic fibrosis ages 2 and older who have at least one of 94 rare mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.